Core Viewpoint - Marvel Biosciences Corp. has awarded 142,987 deferred share units (DSUs) to two directors as a form of compensation instead of cash payment, with the DSUs set to vest on July 31, 2026 [1][2]. Group 1: Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [3]. - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which is the only clinically approved adenosine A2a antagonist [3]. - There is growing scientific evidence suggesting that drugs blocking the adenosine A2a receptor, like MB-204, may be effective in treating various neurological diseases, including autism, depression, and Alzheimer's Disease [3]. - The company is also exploring the potential of MB-204 in addressing neurodevelopmental disorders such as Rett Syndrome and Fragile X Syndrome to broaden its therapeutic applications [3]. Group 2: Financial Details - The deemed value of the awarded DSUs is calculated at $0.16 per share based on the volume-weighted average price (VWAP) of the company's common shares on the TSX Venture Exchange as of July 31, 2025 [2]. - Vested DSUs will be settled upon the directors' separation from the company and will expire 365 days after such separation [2].

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel (“AutoMax”).  As pre ...

Financial Data and Key Metrics Changes - The net asset value (NAV) decreased by $223 million from the third quarter of 2024, primarily due to the decline in CVR Energy and an agreement to sell certain properties in the real estate segment [7][10]. - The investment funds were down approximately 1.6% for the quarter, with the largest decliner being the investment in Caesars [11]. - The company ended the quarter with $1.4 billion in cash and cash equivalents at the holding company and an additional $915 million at the funds [12]. Business Line Data and Key Metrics Changes - Energy segment EBITDA for Q4 2024 was $99 million, down from $204 million in Q4 2023, driven by reduced throughput and lower crack spreads [17]. - The refining margin per throughput barrel decreased to $8.37 from $15.01 in the prior year quarter due to lower crack spreads and unfavorable market derivative valuations [18]. - The automotive segment continues to lag due to previous self-inflicted wounds, but a new CEO has been appointed to implement strategies for remediation [20]. - Real estate adjusted EBITDA decreased by $5 million compared to the prior year quarter, driven by reduced sales of single-family homes [22]. - Food Packaging's adjusted EBITDA decreased by $6 million due to a shift in product mix and lower pricing [23]. - Home fashions adjusted EBITDA increased by $2 million due to lower material costs and improved manufacturing efficiencies [24]. Market Data and Key Metrics Changes - The average realized gate prices for urea were $229 per ton, while ammonia increased by 3% to $475 per ton compared to the prior year quarter [18]. Company Strategy and Development Direction - The company remains focused on building asset value and maintaining liquidity to capitalize on opportunities within and outside existing operating segments [25]. - The management emphasizes an activism strategy, leveraging the Icahn brand name and history to drive shareholder value [46][47]. Management's Comments on Operating Environment and Future Outlook - Management noted that recent improvements in crack spreads could bode well for CVR Energy, and a change in administration may resolve outstanding litigation regarding small refinery exemptions [9]. - The company anticipates that challenges in the automotive segment will be resolved and results normalized by the second half of 2025 [20]. Other Important Information - The board maintained the quarterly distribution at $0.50 per depository unit [13]. - The funds ended the quarter approximately 22% net long, adjusting for refining hedges, the fund was 35% net long [16]. Q&A Session Summary Question: Inquiry about hedge funds' net long position - The net long position was 22%, with a 35% net long excluding energy hedges. The previous position at the end of the third quarter was net short 2% [28][30]. Question: Clarification on real estate segment's indicative net asset value adjustment - The significant increase in indicative net asset value was due to an agreement to sell certain properties that exceeded book value, leading to a revaluation of remaining assets [35][37].